Tuberculosis and HIV infection: A global perspective

Respiration

Volumn 65, Issue 5, 1998, Pages 335-342

  Murray, John F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

Chemoprophylaxis; Extrapulmonary tuberculosis; HIV 1 infection; Multidrug resistance; Pulmonary tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; CHEMOPROPHYLAXIS; DISEASE COURSE; DISEASE PREDISPOSITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; SKIN TEST; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HIV INFECTIONS; HIV-1; HUMANS; TUBERCULOSIS;

EID: 0031781994     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029291     Document Type: Review

References (44)

1. CDC: Tuberculosis morbidity - United States. MMWR 1997;46:695-700.
2. Murray JF: Cursed duet: HIV infection and tuberculosis. Respiration 1990;57:210-220.
3. Raviglione MC, Dye C, Schmidt S, Kochi A: Assessment of worldwide tuberculosis control. Lancet 1997;350:624-629.
4. Dolin PJ, Raviglione MC, Kochi A: Global tuberculosis incidence and mortality during 1990-2000. Bull WHO 1994;72:213-220.
5. Van Cleeff MRA, Chum HJ: The proportion of tuberculosis cases in Tanzania attributable to human immunodeficiency virus. Int J Epidemiol 1995;24:637-642.
6. Gostin LO, Ward JW, Baker AC: National HIV case reporting for the United States. A defining moment in the history of the epidemic. N Engl J Med 1997;337:1162-1167.
7. Mertens TE, Low-Beer D: HIV and AIDS: Where is the epidemic going? Bull WHO 1996; 74:121-129.
8. Elliott AM, Hayes RJ, Halwiindi B, Luo N, Tembo G, Pobee JOM, Nunn PP, McAdam KPWJ: The impact of HIV on infectiousness of pulmonary tuberculosis: A community study in Zambia. AIDS 1993;7:981-987.
9. Theuer CP, Hopewell PC, Elias D, Schecter GF, Rutherford GW, Chaisson RE: Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis 1990;162:8-12.
10. Grzybowski S, Barnett GD, Styblo K: Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuber 1975;50:90-106.
11. Nunn P, Mungai M, Nyamwaya J, Gicheha C, Brindle RJ, Dunn DT, Githui W, Were JO, McAdam KPWJ: The effect of human immunodeficiency virus type-1 on the infectiousness of tuberculosis. Tuber Lung Dis 1994;75:25-32.
12. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR, Hopewell PC: An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment length polymorphism. N ENgl J Med 1992;326:231-235.
13. Small PM, Hopewell PC, Singh SP, Paz Z, Parsonnet J, Ruston DC, Schecter GF, Daley CL, Schoolnik GK: The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703-1709.
14. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, Drucker E, Bloom BR: Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994;330:1710-1716.
15. Kassim S, Sassan-Morokro M, Ackah A, Abouya LY, Digbeu H, Yesso G, Coulibaly I-M, Coulibaly C, Whitaker PJ, Doorly R, Vetter KM, Brattegaard K, Gnaore E, Greenberg AE, Wiktor SZ, De Cock KM: Two-year follow-up of persons with HIV-1-and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995;9:1185-1191.
16. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, Sierra MF, Schoolnik GK: Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-1144.
17. Stanley SK, Ostrowski MA, Justement JS, Gantt K, Hedayati S, Mannix M, Roche K, Schwartzentruber DJ, Fox CH, Fauci AS: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-1230.
18. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J: Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151:129-135.
19. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr: Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-272.
20. Goletti D, Weissman D, Jackson RW, Graham NMH, Vlahow D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS: Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996;157: 1271-1278.
21. Markowitz N, Hansen NI, Wilcosky TC, Hopewell PC, Glassroth J, Kvale PA, Mangura B, Osmond D, Wallace JM, Rosen MJ, Reichman LB: Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993;119:185-193.
22. Chin DP, Osmond D, Page-Shafer K, Glassroth J, Rosen MJ, Reichman LB, Kvale PA, Wallace JM, Poole K, Hopewell PC: Reliability of anergy skin testing in persons with HIV infection. Am J Respir Crit Care Med 1996; 153:1982-1984.
23. CDC: Anergy skin testing and preventive therapy for HIV-infected persons: Revised recommendations. MMWR 1997;46:1-10.
24. Markowitz N, Hansen NI, Hopewell PC, Glassroth J, Kvale PA, Mangura BT, Wilcosky TC, Wallace JM, Rosen MJ, Reichman LB: Incidence of tuberculosis in the United States among HIV-infected patients. Ann Intern Med 1997;126:123-132.
25. Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC: Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis 1987;136:570-574.
26. Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF: Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993;148:1292-1297.
27. Mlika-Cabanne N, Brauner M, Kamanfu G, Grenier P, Nikoyagize E, Aubry P, Larouzé B, Murray JF: Radiographic abnormalities in tuberculosis and risk of coexisting human immunodeficiency virus infection. Methods and preliminary results from Bujumbura, Burundi. Am J Respir Crit Care Med 1995;152:794-799.
28. Mlika-Cabanne N, Brauner M, Mugusi F, Grenier P, Daley C, Mbaga I, Larouzé B, Murray JF: Radiographic abnormalities in tuberculosis and risk of coexisting human immunodeficiency virus infection: Results from Dar es Salaam, Tanzania, and scoring system. Am J Respir Crit Care Med 1995;152:786-793.
29. Post FA, Wood R, Pillay GP: Pulmonary tuberculosis in HIV infection: Radiographic appearance is related to CD4+ T-lymphocyte count. Tuber Lung Dis 1995;76:518-521.
30. Kennedy DJ, Lewis WP, Barnes PF: Role of fiberoptic bronchoscopy in diagnosis of pulmonary tuberculosis in patients at risk for AIDS. Chest 1992;102:1040-1044.
31. Ellner PD, Kiehn TE, Cammarata R, Hosmer M: Rapid detection of pathogenic mycobacteria by combining radiometric and nucleic acid probe methods. J Clin Microbiol 1988;26: 1349-1352.
32. American Thoracic Society: Rapid diagnostic tests for tuberculosis. What is the appropriate use? Am J Respir Crit Care Med 1997;155: 1804-1814.
33. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC: Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991;324:289-294.
34. Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson MP, Atkinson J, Davis H, Boulos R, Quinn TC, Halsey NA: Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without chemotherapy. Am J Respir Crit Care Med 1996;154:1034-1038.
35. Perriëns JH, St. Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, Portaels F, Willame J-C, Mandala JK, Kaboto M, Ryder RW, Roscigno G, Piot P: Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995;332:779-784.
36. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW: The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-526.
37. Cohn DL, Bustro F, Raviglione MC: Drug-resistant tuberculosis: Review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. Clin Infect Dis 1997; 24(suppl 1):121-130.
38. Murray JF: Tuberculose multirésistante. Rev Pneumol Clin 1994;50:260-267.
39. Park MM, Davis AL, Schluger NW, Cohen H, Rom WN: Outcome of MDR-TB patients. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996;153:317-324.
40. Weiss SE, Slocum PC, Blair FX, King B, Nunn M, Matney GB, Gomez E, Foresman BH: The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-1184.
41. USPH/IDSA: Prevention of opportunistic infection working group: USPH/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations. Clin Infect Dis 1995;21(suppl 1):32-43.
42. Hopewell PC: Tuberculosis in persons with human immunodeficiency virus infection: Clinical and public health aspects. Respir Crit Care Med 1997;18:471-484.
43. Grodin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, Klein M, Vaughn A, Besch CL, Perez G, Szabo S, El-Sadr W: A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997;337:315-320.
44. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ: A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997;337:801-808.